Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Lin C, Lin C, Chang Y, et al. Biological Psychiatry. Published online February 2018. DOI: https://doi.org/10.1016/j.biopsych.2017.12.006
Clozapine is the most effective antipsychotic medication currently available to treat psychosis. When it does not have as beneficial an effect as desired, a new NMDA agonist may have something to offer. Sodium Benzoate was shown in this study to be more effective than placebo at doses of one and two grams per day, without significant side-effects. Although the results of this study remain to be replicated before the clinical effectiveness of Sodium Benzoate can be confirmed, it is useful to know there’s a new therapeutic option for this group of people.
http://www.biologicalpsychiatryjournal.com/article/S0006-3223(17)32297-7/fulltext